EXAI

Exscientia plc [EXAI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EXAI Stock Summary

Top 10 Correlated Stocks

EXAI


In the News

07:00 28 Mar 2024 EXAI

Exscientia to Report Full Year 2023 Financial Results on March 21, 2024

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company's website at investors.exscienti.

03:49 28 Mar 2024 EXAI

The Top 3 Healthcare Stocks to Buy on Weakness in 2024

Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ: NVDA ). The sector is also getting a lift from the U.S. Federal Reserve's decision to stop raising rates and its suggestions that it will cut rates later this year.

09:04 28 Mar 2024 EXAI

Exscientia boss departs over relationships with employees

Nasdaq-listed Exscientia shares crashed by more than a fifth as the Oxford-based biotech fired its founder and chief executive over "inappropriate relationships" with two employees. In a statement, the AI-focused drug developer said that Andrew Hopkins's behaviour was inconsistent with “the company's standards and values”.

09:30 28 Mar 2024 EXAI

MoneyShow's Best Investment Ideas For 2024: Part 4

This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.

01:06 28 Mar 2024 EXAI

The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs

Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedures in most pharmaceutical companies, positioning them well to expedite the approval of new drugs for the market.

05:36 28 Mar 2024 EXAI

The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs

Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedures in most pharmaceutical companies, positioning them well to expedite the approval of new drugs for the market.

08:09 28 Mar 2024 EXAI

M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024

Two factors –lower interest rates and the low valuation of many biotech stocks — are likely to result in many biotech companies being acquired in 2024. Lower interest rates will result in many drug maker stocks being acquired because cheaper borrowing costs will make it cheaper for firms to borrow the money that they need to finance deals.

11:17 28 Mar 2024 EXAI

Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?

The consensus price target hints at a 67.8% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

08:15 28 Mar 2024 EXAI

Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now

Exscientia hopes its AI tools will make it easier to discover new medicines. A few big pharma companies seem to think that it's on to something.

11:18 28 Mar 2024 EXAI

Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a Bet

The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 68% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

EXAI Financial details

Company Rating
Neutral
Market Cap
757.13M
Income
-151.93M
Revenue
25.85M
Book val./share
3.16
Cash/share
2.94
Dividend
-
Dividend %
-
Employees
481
Optionable
No
Shortable
Yes
Earnings
20 May 2024
P/E
-3.99
Forward P/E
-6.01
PEG
-7.78
P/S
23.53
P/B
1.54
P/C
1.94
P/FCF
-2.91
Quick Ratio
6.58
Current Ratio
6.67
Debt / Equity
0.05
LT Debt / Equity
0.04
-
-
EPS (TTM)
-1.23
EPS next Y
-0.95
EPS next Q
-0.21
EPS this Y
24.79%
EPS next Y
-23.1%
EPS next 5Y
3.17%
EPS last 5Y
580.57%
Revenue last 5Y
15.89%
Revenue Q/Q
195.48%
EPS Q/Q
-13.79%
-
-
-
-
SMA20
-14.29%
SMA50
-
SMA100
20%
Inst Own
21.27%
Inst Trans
0.8%
ROA
-28%
ROE
-33%
ROC
-0.4%
Gross Margin
-28%
Oper. Margin
-740%
Profit Margin
-588%
Payout
-
Shs Outstand
125.7M
Shs Float
117.93M
-
-
-
-
Target Price
-
52W Range
4.17-9.12
52W High
-36.56%
52W Low
+42.75%
RSI
46
Rel Volume
0.39
Avg Volume
760.47K
Volume
295.48K
Perf Week
-16.76%
Perf Month
-15.28%
Perf Quarter
22.8%
Perf Half Y
13.97%
-
-
-
-
Beta
0.827
-
-
Volatility
0.16%, 0.5%
Prev Close
-1.21%
Price
5.71
Change
-0.7%

EXAI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.550.270.2
Net income per share
00-0.99-1.17-1.46
Operating cash flow per share
00-0.13-0.6-1.18
Free cash flow per share
00-0.33-0.82-1.44
Cash per share
0011.276.013.73
Book value per share
0011.374.743.65
Tangible book value per share
0010.224.343.59
Share holders equity per share
0011.374.743.65
Interest debt per share
000.140.140.04
Market cap
1677.39B1627.88B985.55M650.9M796.1M
Enterprise value
1677.35B1627.81B430.24M56.81M489.46M
P/E ratio
-202.52K-53.61K-20-4.55-4.39
Price to sales ratio
140.48K123.5K35.9519.7831.9
POCF ratio
182.11K-55.73K-147.79-8.89-5.45
PFCF ratio
240.2K-50.19K-60.62-6.48-4.44
P/B Ratio
58.01K20.41K1.741.131.76
PTB ratio
58.01K20.41K1.741.131.76
EV to sales
140.47K123.49K15.691.7319.61
Enterprise value over EBITDA
-192.49K-51.43K-7.58-0.25-2.4
EV to operating cash flow
182.1K-55.73K-64.52-0.78-3.35
EV to free cash flow
240.2K-50.19K-26.46-0.57-2.73
Earnings yield
00-0.05-0.22-0.23
Free cash flow yield
00-0.02-0.15-0.23
Debt to equity
0.050.060.010.030.01
Debt to assets
0.030.040.010.020.01
Net debt to EBITDA
4.572.459.782.591.5
Current ratio
2.354.7112.726.056.22
Interest coverage
-148.04-260.55-244.61-433.94-172.24
Income quality
-0.870.880.090.430.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.520.920.941.410
Research and developement to revenue
0.731.131.614.735.67
Intangibles to total assets
0.0100.090.060.01
Capex to operating cash flow
-0.240.111.440.370.23
Capex to revenue
-0.19-0.24-0.35-0.83-1.33
Capex to depreciation
-2.96-2.22-1.7-2.37-1.71
Stock based compensation to revenue
0.080.210.521.120
Graham number
0015.911.1810.96
ROIC
-0.24-0.32-0.08-0.24-0.41
Return on tangible assets
-0.15-0.29-0.08-0.19-0.28
Graham Net
0010.124.632.41
Working capital
28.29M73.99M723.48M559.57M433.26M
Tangible asset value
28.48M79.33M509.86M529.99M445.59M
Net current asset value
23.84M67.78M711.33M464.18M318.63M
Invested capital
0.050.060.010.030.01
Average receivables
06.92M14.09M36.42M48.45M
Average payables
03.72M6.52M22.85M25.83M
Average inventory
01.52M1.76M272.51K30.26K
Days sales outstanding
226.21178.46289.36566.98669.79
Days payables outstanding
143.4385.52181.04337.7898.7
Days of inventory on hand
-0.3457.2210.330.550
Receivables turnover
1.612.051.260.640.54
Payables turnover
2.544.272.021.083.7
Inventory turnover
-1.08K6.3835.33664.3653.44M
ROE
-0.29-0.38-0.09-0.25-0.4
Capex per share
00-0.19-0.22-0.27

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.060.070.050.020.07
Net income per share
-0.32-0.38-0.31-0.29-0.25
Operating cash flow per share
-0.64-0.47-0.35-0.33-0.27
Free cash flow per share
-0.7-0.54-0.46-0.39-0.31
Cash per share
5.115.963.633.232.94
Book value per share
4.654.73.633.373.16
Tangible book value per share
4.284.313.323.082.87
Share holders equity per share
4.654.73.633.373.16
Interest debt per share
0.060.140.160.150.15
Market cap
901.7M655.4M527.37M580.75M465.55M
Enterprise value
395.06M61.31M351.48M351.3M374.57M
P/E ratio
-5.69-3.48-3.5-4.04-3.73
Price to sales ratio
128.2179.9391.54193.252.41
POCF ratio
-11.54-11.26-12.15-14.07-13.63
PFCF ratio
-10.56-9.81-9.39-12.13-12.19
P/B Ratio
1.581.131.181.391.18
PTB ratio
1.581.131.181.391.18
EV to sales
56.177.4861.01116.8642.17
Enterprise value over EBITDA
-7.95-1.31-9.21-9.16-11.63
EV to operating cash flow
-5.05-1.05-8.1-8.51-10.96
EV to free cash flow
-4.63-0.92-6.26-7.34-9.81
Earnings yield
-0.04-0.07-0.07-0.06-0.07
Free cash flow yield
-0.09-0.1-0.11-0.08-0.08
Debt to equity
0.010.030.040.040.05
Debt to assets
0.010.020.030.030.03
Net debt to EBITDA
10.1912.724.615.982.82
Current ratio
7.556.057.036.886.67
Interest coverage
-464.22-379.75-174.08-170.36-141.52
Income quality
2.010.871.010.971.02
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.641.211.893.871.25
Research and developement to revenue
5.845.245.810.493.57
Intangibles to total assets
0.060.060.060.070.07
Capex to operating cash flow
0.090.150.290.160.12
Capex to revenue
-1.03-1.05-2.22-2.2-0.45
Capex to depreciation
-2.98-2.22-4.07-1.81-0.92
Stock based compensation to revenue
1.421.271.212.270.72
Graham number
5.816.3754.74.22
ROIC
-0.07-0.08-0.08-0.09-0.08
Return on tangible assets
-0.06-0.06-0.07-0.07-0.06
Graham Net
3.874.62.452.152.11
Working capital
576.52M559.57M425.79M389.45M376.57M
Tangible asset value
524.9M529.99M409.27M380.61M357.16M
Net current asset value
483.99M464.18M340.82M309.06M285.77M
Invested capital
0.010.030.040.040.05
Average receivables
35.58M44.43M46.05M44.87M59.53M
Average payables
20.02M28.42M26.14M12.75M10.37M
Average inventory
204.74K138.57K-20.13M-43.8M-23.65M
Days sales outstanding
483.1560.91640.481.46K712.51
Days payables outstanding
172.33291.14160.44149.67137.68
Days of inventory on hand
1.90.47-429.08-678.970
Receivables turnover
0.190.160.140.060.13
Payables turnover
0.520.310.560.60.65
Inventory turnover
47.36190.05-0.21-0.136.74M
ROE
-0.07-0.08-0.08-0.09-0.08
Capex per share
-0.06-0.07-0.1-0.05-0.03

EXAI Frequently Asked Questions

What is Exscientia plc stock symbol ?

Exscientia plc is a GB stock and trading under the symbol EXAI

What is Exscientia plc stock quote today ?

Exscientia plc stock price is $5.71 today.

Is Exscientia plc stock public?

Yes, Exscientia plc is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap